Learning Objectives

Keynote 1 – Understanding rapid acting antidepressants

Dr. John Krystal

 

 

Keynote 2 – Computational models for depression and antidepressant action

Dr. Tiago Maia

 

 

Symposia 1 – Diagnosis and impact of TRD

Prof. Daniel Souery
Definitions of TRD

 

Dr. Koen Demyttenaere
Impact of TRD

 

Dr. Georgios Aislaitner
Health regulatory perspective – EMA

 

 

 

 

Symposia 2 – Atypical antipsychotic augmentation in TRD: an update

Prof. Siegfried Kasper
Clinical background and present state of the art

 

Dr. Ross Baker
Adjunctive brexpiprazole in major depression

 

Dr. Sharon Mates
Novel antipsychotics for TRD

 

Prof. Torgny Svensson
Underlying mechanisms of action, preclinical evidence

 

 

Symposia 3 – The glutamatergic approach for treatment of depression

Prof. Maurizio Popoli
Restoration by ketamine of stress-induced maladaptive plasticity: implications for pathophysiology and treatment

 

Dr. Gerard Sanacora
Insight into rapid acting antidepressants

 

Prof. Kenji Hashimoto
R-Ketamine or S-Ketamine?

 

Dr. Carlos Zarate
Ketamine and beyond

 

 

Symposia 4 – Psychopharmacology and brain stimulation in TRD

Dr. Pierre Blier
Evidence for adding 2 antidepressants in TRD

 

Prof. Maurizio Fava
New Add-on strategies in TRD

 

Dr. Georgios Petrides
Electroconvulsive Treatment in TRD

 

Prof. Thomas Schlaepfer
Neurostimulation in TRD

 

 

Symposia 5 – Results of the European Group for the Study of Resistant Depression

Prof. Siegfried Kasper
The programme of GSRD

 

Dr. Stuart Montgomery
To switch or augment?

 

Dr. Alessandro Serretti
Genetic findings in GSRD and STAR*D

 

Dr. Alexander Kautzky
Machine-learning approach for big data sets

 

 

Symposia 6 – Molecular and brain circuit mechanisms in depression

Dr. Dan Rujescu
Molecular mechanisms of resilience and depression

 

Dr. Alan Frazer
Role of hippocampus-prefrontal cortex circuit for antidepressant response

 

Dr. Rupert Lanzenberger
Circuit mechanisms of reward, anhedonia and depression

 

Dr. John Mann
Postmortem Brain Evidence of Mood Disorders